Delivery Order SPE2DB22D1202-SPE2DB25FVJA4
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $2,648.59 to AmerisourceBergen Drug Corp for Repatha 140 mg/ml SureClick auto-injector pens, with an ultimate completion date of September 12, 2025. This is a firm fixed-price, competitively awarded contract with no set-aside designation. The award reflects AmerisourceBergen's role as a critical pharmaceutical distributor supporting federal medical procurement, particularly for military and veteran healthcare systems. The place of...
- The Defense Logistics Agency awarded a $41,877.63 delivery order to AmerisourceBergen Drug Corp for Repatha 140 mg/mL SureClick auto-injector pens under a firm fixed price contract type. The award was made on September 2, 2025, with an ultimate completion date of September 3, 2025, and represents a non-set-aside competitive procurement. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as the place of performance for this transaction. This delivery order constitutes a...
- The Defense Logistics Agency awarded a delivery order valued at $1,041.42 to AmerisourceBergen Drug Corp for the supply of Repatha 140 mg/ml SureClick auto-injector pens, with an ultimate completion date of August 5, 2025. This non-set-aside, competitively awarded contract employs firm fixed price terms and represents a child delivery order under AmerisourceBergen's larger indefinite delivery contract with DLA Troop Support Medical. The product will be delivered to the company's facility in...
- The Defense Logistics Agency awarded a delivery order valued at $4,165.68 to AmerisourceBergen Drug Corp for the supply of Repatha 140 mg/ml SureClick auto-injector pens. This competitive contract, executed on August 13, 2025, with an ultimate completion date of August 14, 2025, represents a firm fixed-price delivery order with no set-aside designation. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its...
- The Defense Logistics Agency awarded a $22,429.36 delivery order to AmerisourceBergen Drug Corp for Repatha 140 mg/ml SureClick auto-injectors, with an ultimate completion date of September 17, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The product will be supplied to the place of performance in Conshohocken, Pennsylvania,...
- The Defense Logistics Agency awarded a $10,594.36 firm fixed price delivery order to AmerisourceBergen Drug Corp for Repatha 140 mg/ml SureClick auto-injector pens, with an ultimate completion date of September 2, 2025. This non-set-aside award was issued on August 29, 2025, to support federal medical supply needs. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and...
- The Defense Logistics Agency awarded a $27,880.54 delivery order to AmerisourceBergen Drug Corp for Repatha 140 mg/mL SureClick auto-injectors, with an ultimate completion date of September 5, 2025. This non-competitive delivery order represents a firm fixed-price purchase under the company's existing contract vehicle with DLA. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal military and veteran...
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $8,119.28 by the Defense Logistics Agency's Medical Supply Chain on August 18, 2025, for the supply of Repatha 140 mg/ml SureClick auto-injector pens. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at...
- The Defense Logistics Agency awarded a $9,080.88 firm fixed price delivery order to AmerisourceBergen Drug Corp for Repatha 140 mg/ml SureClick auto-injector pens. The award, issued on August 19, 2025, with an ultimate completion date of August 20, 2025, was competitively awarded with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement, particularly...
- The Defense Logistics Agency awarded a delivery order valued at $18,133.57 to AmerisourceBergen Drug Corp for Repatha 140 mg/ml SureClick auto-injector pens, with an ultimate completion date of September 10, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a single delivery order fulfillment. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical vendor for federal...
- SPE2DB22D1202Indefinite Delivery Contract
- SPE2DB22D1202-SPE2DB25FVJA4Delivery Order
The Defense Logistics Agency awarded a $34,197.25 delivery order to AmerisourceBergen Drug Corp for Repatha 140 mg/ml SureClick auto-injector pens, with an ultimate completion date of August 22, 2025. This competitively awarded, firm fixed-price contract contains no set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal medical procurement, with particular focus on supporting military and veteran healthcare systems. The delivery order will be fulfilled from the company's Conshohocken facility. This delivery order is issued under AmerisourceBergen's broader Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. This prime contract vehicle enables comprehensive global pharmaceutical support across multiple therapeutic domains for military healthcare programs worldwide. The Repatha auto-injector, a PCSK9 inhibitor used for cholesterol management, represents a specialty pharmaceutical product aligned with the Defense Health Agency's medical supply requirements for active-duty personnel, beneficiaries, and military healthcare facilities.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $34.2k | 8/21/25 |